Abstract
Interferon (IFN) therapy of early chronic myelogenous leukemia (CML) frequently produces partial or complete cytogenetic remission of the disease. Patients with complete cytogenetic remission often continue on therapy for several years with bone marrow showing only diploid (normal) metaphases. We studied hematopoiesis in five female patients with major cytogenetic remissions from CML during IFN therapy. Clonality analysis using the BstXI PGK gene polymorphism showed that granulocytes were nonclonal in all patients during cytogenetic remission. BCR region studies showed rearrangement only in the one patient whose remission was incomplete at the time of sampling. Granulopoiesis is nonclonal in IFN-induced remissions of CML and may be derived from normal hematopoietic stem cells.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Clone Cells / pathology
-
Female
-
Gene Rearrangement
-
Hematopoiesis*
-
Humans
-
Interferon Type I / therapeutic use
-
Interferon-gamma / therapeutic use
-
Interferons / therapeutic use*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Oncogene Proteins / genetics
-
Protein-Tyrosine Kinases*
-
Proto-Oncogene Proteins c-bcr
-
Proto-Oncogene Proteins*
-
Recombinant Proteins
-
Remission Induction
Substances
-
Interferon Type I
-
Oncogene Proteins
-
Proto-Oncogene Proteins
-
Recombinant Proteins
-
Interferon-gamma
-
Interferons
-
Protein-Tyrosine Kinases
-
BCR protein, human
-
Proto-Oncogene Proteins c-bcr